Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.53 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | IL1B | P01584 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 4/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31557838 | 1.00 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20812351 | 1.00 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24379064 | 1.00 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24379421 | 1.00 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL12041912 | 0.85 | CRBN (0.58) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24379423 | 0.83 | ABCC9 (0.40) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24379144 | 0.79 | CRBN (0.56) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24379156 | 0.79 | CRBN (0.56) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24379153 | 0.79 | CRBN (0.56) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24379147 | 0.79 | CRBN (0.56) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12048747-B2 | Substituted piperidine Degronimers for Target Protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20220313827-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| WO-2022087125-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN | ARVINAS OPERATIONS, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3455219-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2017197051-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| US-20070098631-A2 | DIAGNOSTIC COMPOUNDS COMPRISING A SCAFFOLD COUPLED TO A SIGNAL ENTITY FOR MEDICAL IMAGING DIAGNOSTIC | GUERBET (FR) | 2007-05-03 | — | — | US | disclosed |
| US-20070098631-A2 | DIAGNOSTIC COMPOUNDS COMPRISING A SCAFFOLD COUPLED TO A SIGNAL ENTITY FOR MEDICAL IMAGING DIAGNOSTIC | GUERBET (FR) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070098631-A2 | DIAGNOSTIC COMPOUNDS COMPRISING A SCAFFOLD COUPLED TO A SIGNAL ENTITY FOR MEDICAL IMAGING DIAGNOSTIC | HTR3D, BRD4, CNR1 | CRBN 1262/4885DDB1 677/4885IKZF3 1197/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | CRBN 23/4885DDB1 503/4885IKZF3 3499/4885 |
| US-20220313827-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, NEDD4 | CRBN 77/4885DDB1 769/4885IKZF3 2159/4885 |
| US-12048747-B2 | Substituted piperidine Degronimers for Target Protein degradation | GID4, RNF5, UBE3C | CRBN 105/4885DDB1 716/4885IKZF3 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.